Results 181 to 190 of about 27,323 (260)

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, Volume 20, Issue 8, Page 1963-1985, August 2026.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors. [PDF]

Oncologist
Sun H, Chen G, Xue J, Zhang Y, Ma Y, Yang Y, Fang W, Zhao Y, Huang Y, Hong S, Zhou T, Zhao S, Zhou H, Chen X, Li J, Zhang L, Zhao H.   +16 more
europepmc   +1 more source

Affinity‐Tuned Albumin Hitchhiking Extends the Bioorthogonal Capture Window in Pretargeting Radiotheranostics

Advanced Healthcare Materials, Volume 15, Issue 29, 7 August 2026.
Pharmacokinetic engineering of clickable radioligands was achieved via albumin hitchhiking approach within a pretargeted radiotheranostics delivery platform. This approach reduced rapid renal elimination, expanded bioorthogonal capture window, boosted tumor uptake by ∼3.5‐fold, and improved the tumor‐to‐liver ratio by ∼6‐fold.
Xie He, Nicholas L. Fletcher, Gayathri R. Ediriweera, Yifei Zhu, James Humphries, Christopher B. Howard, Jiazheng Wang, Craig A. Bell, Kristian Kempe, Kristofer J. Thurecht   +9 more
wiley   +1 more source

Vascular Endothelial Growth Factor/Angiopoietin-2 Bispecific Antibody-Induced Vascular Normalization: From Basic Mechanisms to Therapeutic Applications in Breast Cancer. [PDF]

Immun Inflamm Dis
Li M, Han F, Ling S, Su X, Zhao Y, Lv S, Zhang X.   +6 more
europepmc   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, Volume 13, Issue 44, 7 August 2026.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

Linvoseltamab in multiple myeloma: a BCMA × CD3 bispecific antibody for relapsed and refractory disease. [PDF]

Ann Med Surg (Lond)
Khan G, Haider E, Imtiaz A, Ekouo J.
europepmc   +1 more source

Epitope‐Resolved Digital SERS Profiling of Structurally Dynamic Antigens via a Multi‐Epitope Bispecific Antibody Framework

Advanced Science, Volume 13, Issue 46, 17 August 2026.
A multi‐epitope digital surface‐enhanced Raman spectroscopy framework enables epitope‐resolved immunoprofiling by integrating bispecific antibody fragments with spectrally encoded nanotags. This approach decouples binding events into independent digital channels, allowing structure‐aware antigen analysis.
Jing Wang, Quan Zhou, Kym Lowry, Christopher B. Howard, Matt Trau   +4 more
wiley   +1 more source

Pseudoprogression of bladder extramedullary disease of multiple myeloma following the treatment with elranatamab, an anti-BCMA/CD3 bispecific antibody. [PDF]

J Clin Exp Hematop
Ito K, Okamoto H, Maekura C, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kuroda J.   +7 more
europepmc   +1 more source

Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis

American Journal of Hematology, Volume 101, Issue 8, Page 1903-1914, August 2026.
ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM ...
Maximilian J. Steinhardt, Ute Hegenbart, Tamer Hellou, Sara Oubari, Murielle Roussel, Rahel Schwotzer, Francis Buadi, David Dingli, Moritz Binder, Taxiarchis Kourelis, Saurabh S. Zanwar, Max J. Rieger, Caroline Morbach, Vladimir Cejka, Bernhard Gerber, Stefan Störk, Hermann Einsele, Shaji Kumar, Morie Gertz, Alexander Carpinteiro, K. Martin Kortum, Eli Muchtar, Angela Dispenzieri, Stefan Schönland   +23 more
wiley   +1 more source

BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings. [PDF]

Cancer Res Commun
Harding JJ, Hofheinz R, Élez E, Kuboki Y, Rasco DW, Cecchini M, Shen L, He M, Archuadze S, Chhaya N, Haderk F, Mészáros L, Wölke S, Katakabe T, Lorence RM, Van Cutsem E, Kopetz S, Pant S.   +17 more
europepmc   +1 more source